Bristol Myers Squibb and bluebird bio return to FDA; Takeda gets a breakthrough nod
More than two months after the FDA slammed Bristol Myers Squibb and bluebird bio with a suprise refuse-to-file on their “ide-cell” CAR-T therapy, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
